# Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders

> **NCT02823210** · — · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 300 (estimated)

## Conditions studied

- Myeloproliferative Neoplasms

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02823210
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2018-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02823210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02823210, "Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02823210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*